SAB Biotherapeutics, Inc. (SABS) Fair Value 2026

SABS · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

5.2 /10

32 fundamental signals · 3 models active

Value Trap Risk

DANGER (65/100)

Quick Summary — As of 2026-08-28, SAB Biotherapeutics, Inc. (SABS) trades at $3.79, versus a $0.64 median fair value across its 3 active models — 83.1% below the current price. QOC: 5.2/10. Value Trap Risk: 65/100 (DANGER). 3/13 models active. Within that set, the Bayesian DCF component alone returns $0.35.

Key Facts

Ticker
SABS
Price
$3.79
Quality Score
5.2/10
Value Trap Risk
65/100
Models Active
3/13
Last Updated
Strength: 3 independent models provide multi-angle coverage
Risk: Value Trap score of 65 suggests caution despite apparent undervaluation

Is SAB Biotherapeutics, Inc. (SABS) Undervalued or Overvalued in 2026?

According to CirclFi’s 3-model valuation engine, SAB Biotherapeutics, Inc. (SABS) appears overvalued as of : the median of 3 independent fair value estimates is $0.64, 83.1% below the current price of $3.79. Estimates range from $0.35 to $1.63. SABS scores 5.2/10 on fundamental quality and 65/100 on value-trap risk.

For context, the median US equity CirclFi rates trades at an implied -23.4% versus its own 13-model consensus, across 3,809 rated companies as of 2026-08-28. SABS’s -83.1% gap is wider than that market norm, and the Biotechnology sector median is -64.7%. Full market index →

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy SAB Biotherapeutics, Inc. Stock in 2026? →

What Fair Value Does Each Model Give SABS?

3 Intrinsic Value Models vs. Current Price ($3.79)

Core Models (Unlocked)
Model Fair Value Upside
Intrinsic · Low Conviction
 $0.35 -90.7%
Intrinsic · Medium Conviction
 $1.63 -57.0%
Relative · Low Conviction
 $0.64 -83.1%

All Models Active

All 3 models are displayed above.

What Is SABS's Fair Value Range?

Spread across 3 independent models · $0.35 to $1.63

CirclFi's 3 active models place SAB Biotherapeutics, Inc. (SABS) between $0.35 and $1.63 per share, a spread of 199% of the median. The median of that range — $0.64 — is the fair value CirclFi publishes for SABS, against a current price of $3.79.

Low · Bayesian DCFHigh · RCMH-DCF
$0.35median $0.64$1.63
Where the range comes from
Most bearish modelBayesian DCF$0.35
Most bullish modelRCMH-DCF$1.63
Model agreement0 bullish · 3 bearishwide

A band this wide is itself the finding. When independent methods land far apart, they are reading a business whose value depends heavily on which lens you apply — volatile earnings, heavy reinvestment, or an asset base that cash-flow and asset-based methods score differently. That disagreement is information: it says the choice of method matters more than usual for SABS. Treat the median as one reading among several and compare the individual models below before acting.

Every figure above is one model's standalone output on SABS, not a CirclFi price target. How each model works →

What Is SAB Biotherapeutics, Inc. (SABS) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, SAB Biotherapeutics, Inc.'s intrinsic value is estimated at $0.64, suggesting the stock is overvalued at its current price of $3.79. With 3 out of 3 models flagging downside (-83.1% vs price), the market may be pricing in unsustainable growth. The most optimistic model, RCMH-DCF, places fair value at $1.63 (-57.0%), while Bayesian DCF — the most conservative — estimates $0.35 (-90.7%). This +33.8% gap reflects genuine analytical uncertainty about SAB Biotherapeutics, Inc.'s intrinsic worth.

What Do the Models Say About SABS?

3 of 13 models are currently active for SABS. All 3 active models suggest the stock trades above fair value. Taken together, their median fair value for SABS is $0.64 — the figure CirclFi publishes as this stock's fair value. One component of that median, the Bayesian DCF, returns $0.35 on its own, implying -90.7% downside from the current price. See which stocks rank higher →

How Does SABS Rank in Biotechnology?

Among 625 Biotechnology stocks, SABS ranks #269 by Quality of Company score. CirclFi's QOC score of 5.2/10 evaluates 32 fundamental signals. A score of 5.2 reflects mixed fundamentals.

See all Most Undervalued Biotechnology Stocks →

As a biotech sector, SAB Biotherapeutics, Inc. operates in a sector where partnership revenue is a critical driver of valuation. Investors evaluating SABS should weigh these sector-specific dynamics alongside our model-derived fair values.

Is SABS a Value Trap?

CirclFi's Value Trap algorithm assigns SABS a score of 65/100 (DANGER). This is a high-risk signal. Deteriorating fundamentals suggest the discount may be justified. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

3 of 13 models are active for SAB Biotherapeutics, Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi 32-factor quality framework, SAB Biotherapeutics, Inc.'s fundamental quality profile registers 5.2/10. This mixed score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record. Investors should note the company's elevated value trap risk score, which suggests apparent undervaluation may not be what it seems.

The gap between the most bullish and bearish model spans +33.8% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every SABS valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across SABS's 3 active models, average confidence is 19%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy SAB Biotherapeutics, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

ALXOALX Oncology Holdings Inc.QOC 5.2IMTXImmatics N.V.QOC 5.2NKTXNkarta, Inc.QOC 5.2ALMSAlumis Inc.QOC 5.2MLECMoolec Science SAQOC 5.2NEUPNeuphoria Therapeutics Inc.QOC 5.2BRNSBarinthus Biotherapeutics plcQOC 4.6KLRAKailera Therapeutics, Inc.QOC 3.4VTGNVistagen Therapeutics, Inc.QOC 6.3EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: ALXO · IMTX · NKTX · ALMS · MLEC · NEUP · BRNS · KLRA · VTGN · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to SABS?

6 companies across all industries closest to SABS’s Quality of Company score of 5.2/10.

REEDReed's, Inc.QOC 5.2CATXPerspective Therapeutics, Inc.QOC 5.2IDAIT Stamp Inc.QOC 5.2FOFAFamily Office of America Inc.QOC 5.2ASTCAstrotech CorporationQOC 5.2NVDANVIDIA CorporationQOC 10.0

Read investment analysis: REED · CATX · IDAI · FOFA · ASTC · NVDA

Where Does SABS Sit in CirclFi's Biotechnology Rankings?

SABS is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About SAB Biotherapeutics, Inc.’s Valuation?

What is SAB Biotherapeutics, Inc.'s intrinsic value in 2026?

CirclFi puts SAB Biotherapeutics, Inc. (SABS)'s intrinsic value at $0.64 — the median of 3 independent model estimates as of 2026-08-28, ranging from $0.35 to $1.63. One component of that median, the Bayesian DCF, runs 10,000 Monte Carlo simulations with jump-diffusion and returns $0.35 on its own. The Quality of Company score is 5.2/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is SABS overvalued or undervalued right now?

At $3.79, 0 of 3 active models suggest SABS may be undervalued, while 3 indicate potential overvaluation. The median of all 3 fair value estimates is $0.64, 83.1% below the current price of $3.79 — a consensus view that SABS is overvalued. The assessment depends on which methodology best fits SAB Biotherapeutics, Inc.'s business model in Biotechnology.

What does a Quality of Company score of 5.2 mean for SABS?

SAB Biotherapeutics, Inc.'s QOC of 5.2/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on SABS?

CirclFi analyzes SABS with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 3 of 13 are active for this stock. Read the full methodology →

Which valuation models are most bullish and most bearish on SABS?

Of the 3 models currently active on SABS, RCMH-DCF is the most bullish at $1.63 per share, and Bayesian DCF is the most bearish at $0.35. CirclFi's published fair value for SABS is the median of that range, $0.64, not either extreme. The gap between the two ends equals 199% of the median — a wide spread, meaning the methods genuinely disagree and the median should carry less weight. Browse stocks by value-trap risk →

Is SABS a value trap in 2026?

SAB Biotherapeutics, Inc.'s Value Trap score is 65/100 (DANGER). This elevated score suggests the stock may look undervalued but faces deteriorating fundamentals — declining margins, rising debt, or shrinking revenue could make the apparent discount deceptive. Browse our ranked stock lists to compare value-trap scores across industries.

Cite this analysis — “According to CirclFi’s 3-model valuation engine, SAB Biotherapeutics, Inc. (SABS) has a median fair value of $0.64 — 83.1% below the current price of $3.79 — as of 2026-08-28.” Source: circlfi.com/stock/SABS/ · Methodology
Primary sources for this SABS valuation
  • Financial statements: SAB Biotherapeutics, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001833214) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for SABS as of ; valuations recomputed .